Compare Invesco Solar ETF (TAN) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco Solar ETF vs Viatris Inc — how do they compare? Invesco Solar ETF trades at $53.77, while Viatris Inc trades at $17.15 (market cap $19.79B). The key difference: Viatris Inc pays a 2.83% dividend while Invesco Solar ETF pays none, and Viatris Inc is trading nearer its 52-week high, Invesco Solar ETF nearer its low. Which is the better fit depends on your goals.
| TAN | VTRS | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $73.95 | $17.39 |
52-Week Low | $36.07 | $8.74 |
Market Cap | — | $19.79B |
Enterprise Value | — | $32.00B |
Dividend Yield | — | 2.83% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TAN trades at $52.69, down 2.24% with bearish technical signals showing 17 sell indicators versus 1 buy. The ETF faces headwinds from lower oil prices and regulatory uncertainty, though it benefits from growing data center energy demand and clean energy investment trends. Recent news highlights both opportunities in the AI-driven power boom and challenges from permit delays and geopolitical tensions affecting solar development.
The outlook remains cautious with technical deterioration and mixed sentiment. Long-term growth potential exists from energy transition trends, but near-term volatility and policy risks require careful monitoring. Investors should weigh exposure to utility-scale solar against competitive pressures and regulatory headwinds.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Invesco Solar ETF
TAN is a thematic ETF that tracks the MAC Global Solar Energy Index. It provides targeted exposure to the global solar industry, including manufacturers of solar panels, installers, and component suppliers like Enphase and First Solar.
Read more on TAN →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
